Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy
复制标题
DOI：
10.1016/j.ygyno.2008.11.010
复制
发表时间：
2009-03-01
影响因子：
4.7
通讯作者：
Aghajanian, C.
中科院分区：
文献类型：
--
作者：
Zivanovic, O.;Leitao, M. M., Jr.;Aghajanian, C.
目标.分析宫颈小细胞神经内分泌癌（SCNEC）患者的无进展生存期（PFS）和总生存期（OS），并确定含铂联合化疗是否对该人群有益。我们对1990年1月至2007年2月期间在我们机构接受治疗的所有SCNEC患者进行了回顾性分析。如果病理诊断在我们的机构没有得到证实，则患者被排除。采用标准统计方法。17例患者符合入选标准。整个组的估计3年PFS和OS率分别为22%和30%。中位进展时间为9.1个月。疾病程度是唯一有意义的预后因素。早期疾病患者（IA 1-IB 2）的中位OS为31.2个月，晚期疾病患者（IIB-IV，P=0.034）为6.4个月。在早期疾病组中，接受化疗的患者3年无远处复发生存率为83%，未接受化疗作为初始治疗的患者为0%（P=0.025）。接受化疗患者的3年OS率为83%，未接受化疗患者的3年OS率为20%（P=0.36）。鉴于SCNEC的罕见性，该回顾性分析仅限于少数患者。然而，这种罕见疾病的自然史类似于小细胞肺癌，并且由于肿瘤的远处扩散倾向，预后很差。治疗应符合小细胞肺癌的治疗。(C)2008年爱思唯尔公司All rights reserved.
Objectives. To analyze progression-free (PFS) and overall survival (OS) in patients with small cell neroendocrine carcinoma of the cervix (SCNEC), and to determine whether platinum-based combination chemotherapy is beneficial for this Population.Methods. We Performed a retrospective analysis of all patients with SCNEC who were treated at our institution between 1/1990 and 2/2007. Patients were excluded if pathologic diagnosis was not confirmed at Our institution. Standard statistical methods were utilized.Results. Seventeen patients met inclusion criteria. The estimated 3-year PFS and OS rates for the entire group were 22% and 30%, respectively. Median time to progression was 9.1 months. Extent of disease was the only significant prognostic factor. Median OS for patients with early stage disease (IA1-IB2) was 31.2 months and 6.4 months for patients with advanced stage disease (IIB-IV, P=0.034). In the early-stage disease group, the 3-year distant recurrence-free survival rate was 83% for patients who received chemotherapy and 0% for patients who did not receive chemotherapy as part of their initial treatment (P=0.025). The estimated 3-year OS rate was 83% for patients who received and 20% for patients who did not receive chemotherapy as part of their initial treatment (P=0.36).Conclusion. Given the rarity of SCNEC this retrospective analysis is limited by a small number of patients. However, the natural history of this rare disease is akin to small cell lung cancer and the prognosis is poor due to the tumor's propensity for distant spread. The treatment should conform to the treatment of small cell lung cancer. (C) 2008 Elsevier Inc. All rights reserved.